

PRODUCT INFORMATION

Common Name	FPA-008,FPA008
Conjugate	Unconjugated
Synonyms	CSF1R;C-FMS;CD115;CSFR;FIM2;FMS;M-CSFR
Applications	ELISA; Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG4 - Kappa
Reactivity	Human
Target	CSF1R
Uniprot ID	P07333
Description	Anti-CSF1R(cabiralizumab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-CSF1R (cabiralizumab biosimilar) mAb ELISA

0.1µg of Human CSF1R, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 1 µg/ml (100 µl/well) Human CSF1R , His tagged protein PME100067 can bind Anti-CSF1R Neutralizing antibody (BME100055) in a linear range of 0.2-16 ng/ml.




Figure 2. Flow cytometry analysis with Anti-CSF1R mAb 1 µg/ml (cabiralizumab) on HEK293 cells transfected with human CSF1R (Blue histogram)or HEK293 transfected with irrelevant protein(Red histogram) .




**A**

Figure 3. Flow cytometry analysis of antigen binding of anti-human CSF1R mAb(BME100055).
(A) A clear peak shift of BME100055 was seen compared to the control when incubated with CSF1R-expressing THP-1 cells, indicating strong binding of BME100055 to CSF1R. Antibodies were incubated at 2 μ g/mL.

